Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | PDE5A | O76074 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108277 | 0.84 | DNMT1 (0.36) | CYP2A6CYP2C19MAPTNPC1CYP1A2 | |
| SCHEMBL15087867 | 0.80 | PDE5A (0.38) | CYP2A6CYP2C19PDE5AALDH1A1KDM4E | |
| SCHEMBL18793016 | 0.75 | — | — | |
| SCHEMBL823939 | 0.75 | — | — | |
| SCHEMBL3327076 | 0.75 | RAB9A (0.41) | ALDH1A1KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1097916 | 0.72 | KMO (0.36) | CYP2C19KDM4EMAPTNPC1CYP1A2 | |
| SCHEMBL823936 | 0.71 | ALDH1A1 (0.46) | CYP2C19ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL24304833 | 0.70 | ALDH1A1 (0.55) | CYP2A6CYP2C19PDE5AALDH1A1KDM4E | |
| SCHEMBL18171776 | 0.70 | GABRA1 (0.41) | ALDH1A1KDM4EMAPTSMN1; SMN2TP53 | |
| SCHEMBL1098144 | 0.69 | CYP2A6 (0.49) | CYP2A6ALDH1A1MAPTHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | SOBI, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| EP-1951729-B1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CELL THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885CYP2C19 2643/4885PDE5A 2545/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885CYP2C19 2643/4885PDE5A 2545/4885 |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | CYP2A6 3291/4885CYP2C19 4344/4885PDE5A 3776/4885 |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885CYP2C19 2643/4885PDE5A 2545/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | CYP2A6 2330/4885CYP2C19 2643/4885PDE5A 2545/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | CYP2A6 2330/4885CYP2C19 2643/4885PDE5A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.